and is associated with postprocedural cardiovascular morbidity and mortality. Limited data have been reported about the occurrence of myocardial damage associated with transcatheter aortic valve implantation (TAVI). Therefore, our purpose was to investigate the incidence, predictors, and prognostic value of myocardial injury during TAVI. Methods and Results-We studied 119 patients (aged 81Ϯ8 years; 47 male) who had undergone a TAVI with the Medtronic-CoreValve bioprosthesis. Serum creatine kinase-MB (CK-MB) and cardiac troponin T (cTnT) levels were measured before and after the procedure. Myocardial injury was defined as a postprocedural increase of CK-MB and/or cTnT level Ͼ5 times the upper reference limit. After TAVI, the incidence of myocardial injury was 17%, which was independently predicted by procedural duration (in minutes) (odds ratio [OR], 1.04; 95% CI, 1.01-1.06), preprocedural ␤-blocker use (OR, 0.12; 95% CI, 0.03-0.45), peripheral arterial disease (OR, 6.36; 95% CI, 1.56 -25.87), and prosthesis depth (in millimeters) (OR, 1.31; 95% CI, 1.08 -1.59). The 30-day mortality after TAVI was 13% and was independently predicted by myocardial injury (OR, 8.54; 95% CI, preprocedural hospitalization (OR, 9.36; 95% CI,, and left ventricular mass index (in g/m 2 ) (OR, 1.02; 95% CI, 1.00 -1.03). Conclusions-After transcatheter aortic valve implantation, serum levels of both CK-MB and cTnT increase, reflecting the occurrence of periprocedural myocardial injury. A longer procedural duration, the absence of ␤-blocker use, peripheral arterial disease, and a deeper prosthesis insertion are associated with myocardial injury. Together with preprocedural hospitalization and left ventricular mass, myocardial injury is an independent predictor for 30-day mortality after TAVI.
T ranscatheter aortic valve implantation (TAVI) is a novel technique, which in the past few years has evolved as an effective alternative treatment of severe degenerative aortic valve stenosis in patients rejected for conventional surgical valve replacement or who have a high risk for perioperative and postoperative morbidity and mortality. [1] [2] [3] [4] [5] [6] [7] [8] Perioperative myocardial injury, manifested as myocardial stunning or infarction, is a frequent complication during cardiac surgery and percutaneous coronary intervention (PCI) and is strongly associated with postprocedural cardiovascular morbidity and mortality. 9 -18 In the setting of cardiac surgery, myocardial damage is caused by direct myocardial trauma and, more important, by global myocardial ischemia during aortic crossclamping and cardiac arrest, and by insufficient myocardial protection. 10,11,19 -23 In some patients, reperfusion injury may play a role. 24, 25 Because there is no need for cardioplegia and aortic cross-clamping during TAVI, myocardial injury is expected to be less. However, myocardial damage during TAVI could be caused by periprocedural conditions, resulting in myocardial oxygen supply-demand mismatch, such as balloon valvuloplasty, acute aortic regurgitation, and temporary hypotension during rapid ventricular pacing and gradual deployment of the bioprosthesis. Furthermore, direct myocardial injury by catheter, wire, and prosthesis manipulation may play a role. As in PCI, 26, 27 another potential mechanism for myocardial injury during TAVI is particle embolization into the coronary arteries, arising from the mentioned manipula-tion at the calcified aortic valve leaflets. On the other hand, cardioprotective effects of certain preprocedural medication may protect the myocardium from damage during TAVI. Therefore, the purpose of this study was to investigate the incidence, predictors, and prognostic value of myocardial injury during TAVI.
WHAT IS KNOWN
• Periprocedural myocardial injury is known to be a clinically relevant complication during cardiac surgery and percutaneous coronary intervention. • Transcatheter aortic valve implantation is a novel treatment of patients with symptomatic aortic valve stenosis, in which the occurrence and clinical relevance of myocardial injury has been inadequately described.
WHAT THE STUDY ADDS
• This study describes the predictors and prognostic value of myocardial injury in the setting of transcatheter aortic valve implantation (TAVI) with the Medtronic-CoreValve device. • Preventive measures to reduce the amount of myocardial injury could be of positive influence for clinical outcome after TAVI. • Future studies with larger patient populations are needed for further examination.
Methods

Patients
In a prospective, single-center, observational study, 119 consecutive patients were included, in whom a transcatheter aortic valve implantation with the Medtronic-CoreValve bioprosthesis (Corevalve Inc; Irvine, CA) was planned, via the retrograde transfemoral approach, between October 2007 and June 2011. All patients were selected for TAVI based on their symptomatic severe degenerative aortic valve stenosis and because they were rejected or had a high risk for conventional aortic valve surgery due to older age and comorbidity. The clinical and anatomical criteria for selection of patients for TAVI with the third-generation 18F Medtronic-CoreValve device are described elsewhere. 2, 4 Patients who died within 12 hours after the procedure (nϭ3), precluding adequate assessment of postprocedural cardiac enzyme serum levels, were excluded, as were patients in whom cardiac enzymes were not assessed until they reached their peak level (nϭ3) and patients who underwent concomitant PCI during the TAVI procedure (nϭ2). All patients underwent coronary angiography as part of the screening for TAVI. In case of significant coronary artery disease, the strategy was to treat all significant coronary artery lesions (Ն70% stenosis) by PCI, where possible. Percutaneous coronary intervention was performed at least 1 week before TAVI.
All patients were pretreated with aspirin and clopidogrel, with a loading dose of 300 mg, where needed. After TAVI, daily aspirin was continued for life-long and daily clopidogrel for at least 3 months after the procedure. Patients who used coumarins (nϭ42) had to discontinue with them at least 3 days before TAVI. In case of coumarin use and a CHADS (Cardiac failure, Hypertension, Age, Diabetes, Stroke) score of Ն3, low-weight molecular heparin was given in a therapeutic dose for at least 2 days before TAVI. All patients received low-weight molecular heparin in a prophylactic dose after TAVI, to prevent thromboembolic events. Of the 39 patients with atrial fibrillation before TAVI, 32 received coumarin treatment.
Implantation of the third-generation 18F Medtronic-CoreValve aortic valve bioprosthesis was performed in the catheterization laboratory under general anesthesia (nϭ62) or only sedation (nϭ57). The procedural technique of TAVI with the Medtronic-CoreValve bioprosthesis has been previously described. 1, 4, 28 Heparin was given during the procedure at a dose of Ϸ100 IU/kg, aimed at an activated clotting time of 300 seconds. All patients treated in our percutaneous valve program have been entered in a prospectively designed protocol and dedicated database.
Blood Sampling and Analysis
Venous blood samples were drawn 1 day before TAVI and at 1, 6, 12, 18, 24, and 30 hours after the procedure until serum levels of creatine kinase-MB (CK-MB) and cardiac troponin T (cTnT) reached their peak and started to decrease. Before analysis, the blood samples were centrifuged at 1000g and stored at -20°C. The serum levels of CK-MB and cTnT were determined by using an electrochemiluminescence immunoassay on the Roche Elecsys 2010 immunoassay analyzer (Roche Diagnostics GmbH; Mannheim, Germany). The upper reference limit (URL) (99 th percentile) was 5.2 ng/mL for CK-MB and 0.1 ng/mL for cTnT. Myocardial injury was defined as postprocedural elevations of serum CK-MB or cTnT levels Ͼ5 times the URL with or without new Q waves or new wall motion abnormalities.
Periprocedural myocardial infarction was defined as postprocedural elevations of serum CK-MB and/or cTnT levels Ͼ5 times the URL in combination with either new Q waves and/or echocardiographically determined new persistent wall motion abnormalities, as obtained from the Valve Academic Research Consortium consensus definitions of end points after TAVI. 29
Evaluation of Other Parameters
A 12-lead ECG was recorded 1 day before TAVI, direct after TAVI, and every day after the procedure until discharge. Transthoracic echocardiography was performed within 3 months before TAVI and within a week postprocedurally, using the GE Vivid 7 machine (GE Healthcare; Horten, Norway). Aortic (prosthetic) valve hemodynamics were assessed before and after TAVI and included aortic valve effective orifice area, peak and mean aortic valve pressure gradient, and (paravalvular) aortic regurgitation grade. Other echocardiographical parameters assessed before and after TAVI were as follows: global left ventricular systolic function, left ventricular internal and wall dimensions, mitral regurgitation grade, and pulmonary artery pressure. Left ventricular mass was calculated using the corrected formula from Devereux et al. 30 Preprocedural hospitalization was defined as hospital admission for at least 1 week just before the TAVI procedure because of severe symptomatic disease, directly or indirectly related to aortic valve stenosis. Significant coronary artery disease was defined as the presence of at least 1 unrevascularized coronary artery stenosis of Ͼ50% before TAVI.
Clinical Outcomes
Clinical outcomes included the following: (1) 30-day all-cause mortality; (2) major cardiac events occurring between 1 and 30 days after TAVI, including low cardiac output (requiring medical or mechanical left ventricular support), perioperative myocardial infarction (postprocedural elevations of serum CK-MB or cTnT levels Ͼ5 times the URL in combination with new Q waves and/or echocardiographically determined new persistent wall motion abnormalities, as obtained from the Valve Academic Research Consortium consensus definitions) 29 ; and sustained ventricular arrhythmia. The Valve Academic Research Consortium-combined safety end point is defined as the occurrence of any 1 of the following events up to 30 days after the procedure: all-cause mortality, major stroke, lifethreatening or disabling bleeding, acute kidney injury (stage 3), periprocedural myocardial infarction, and repeat procedure for valve-related dysfunction (surgical or interventional therapy). 31 A stepwise logistic regression analysis, including all variables with PϽ0.1 in the univariable analysis, was used to determine the predictive factors of both myocardial injury and 30-day mortality. Cumulative survival plots of patients with and without myocardial injury were estimated using the Kaplan-Meier method. The log-rank test was used to compare the difference in survival between both groups of patients. To identify predictors of death within 1 year after TAVI, a Cox proportional hazard model was applied. Results are reported as adjusted hazard ratio (HR) with 95% CI. PϽ0.05 was considered to be significant. Statistical analysis was performed using the statistical software SPSS 17.0 for windows (SPSS Inc; Chicago, IL).
Results
Preprocedural, periprocedural, and postprocedural characteristics of the 119 patients are summarized in Table 1 . The mean age was 81Ϯ8 years, and 47 (39%) of the patients were male. Two concomitant PCIs and 1 valve-in-valve procedure (implantation of a CoreValve in a CoreValve prosthesis, because the first one was inserted in a too high position) were performed. The mean duration of the TAVI procedure was 80Ϯ23 minutes. The 30-day mortality rate was 15 (13%), which included 9 noncardiac deaths (due to pulmonary failure, infectious complications, or stroke) and 6 cardiac deaths (due to terminal heart failure), all occurring between 1 week and 30 days after the procedure. Cardiac events within 30 days after TAVI occurred in 16 patients, which all involved a low cardiac output syndrome, requiring intravenous therapy with inotropics and/or diuretics. The cumulative 1-year mortality rate was 30 (25%), which included 13 noncardiac deaths and 17 cardiac deaths.
After TAVI, CK-MB and cTnT serum levels increased in all patients compared with baseline and reached values higher than the URL. The mean CK-MB level increased from 3.8Ϯ1.3 ng/mL at baseline to a peak of 15.9Ϯ15.8 g/L (PϽ0.0001), which occurred 9.5Ϯ7.0 hours after the procedure. The mean serum concentration of cTnT increased from 0.04Ϯ0.03 to 0.28Ϯ0.30 ng/mL at peak (PϽ0.0001), which was reached 14.3Ϯ11.2 hours after TAVI. Twenty patients had postprocedural peak values Ͼ5 times the URL of one or both serum markers. Seventeen patients had postprocedural CK-MB peak values of Ͼ5 times the URL. No periprocedural myocardial infarction had occurred in these patients, as defined by the previously stated Valve Academic Research Consortium criteria, because they had no new Q waves or echocardiographically determined new wall motion abnormalities. Mean concentrations, as a multiple of the URL, of serum CK-MB and cTnT levels before and at different time points after TAVI are shown in Figure 1 .
Predictors for Myocardial Injury
Periprocedural myocardial injury occurred in 20 (17%) of the patients (Table 1) . Compared with the patients without myocardial injury (nϭ99), the patients with myocardial injury had a lower body mass index (25.2Ϯ4.7 versus 28.2Ϯ5.5 kg/m 2 ; Pϭ0.010), used less ␤-blocker (30% versus 61%; Pϭ0.014), were treated less with only sedation (25% versus 53%; Pϭ0.029), had a deeper prosthesis insertion (8.7Ϯ3.2 versus 6.7Ϯ3.0 mm; Pϭ0.005), and had a longer procedural duration (93Ϯ30 versus 77Ϯ21 minutes; Pϭ0.031). The independent predictors for myocardial injury are shown in Table 2 and included preprocedural ␤-blocker use (odds ratio [OR], 0.12; 95% CI, 0.03-0.45), procedural duration (in minutes) (OR, 1.04; 95% CI, 1.01-1.06), prosthesis depth (in millimeters) (OR, 1.31; 95% CI, 1.08 -1.59), and peripheral arterial disease (OR, 6.36; 95% CI, 1.56 -25.87).
Univariate predictors for CK-MB peak levels Ͼ5 times the URL are somewhat different (see Appendix I in the onlineonly Data Supplement). Figure 2 shows the differences in peak CK-MB and cTnT serum levels between 2 groups that have been divided based on these 4 independent predictors.
Predictors for 30-Day Mortality
The 30-day mortality rate was 15 (13%) and was associated with a higher Society of Thoracic Surgeons risk score (7.8Ϯ3.7 versus 5.9Ϯ4.6; Pϭ0.013), more preprocedural hospitalization (60% versus 16%; Pϭ0.001), a higher left ventricular mass index (181.5Ϯ45.6 versus 147.5Ϯ44.7; Pϭ0.008), and a higher incidence of myocardial injury (47% versus 13%; Pϭ0.004) and postprocedural aortic regurgitation grade Ն3 (20% versus 4%; Pϭ0.042) ( Table 3 ). Multivariate analysis revealed myocardial injury (OR, 8.54; 95% CI, 2.17-33.52), preprocedural hospitalization (OR, 9.36; 95% CI, 2.55-34.38), and left ventricular mass index (in g/m 2 ) (OR, 1.02; 95% CI, 1.00 -1.03) to be independent predictors for 30-day mortality ( Table 4 ).
Predictors for 1-Year Cumulative Mortality
The Kaplan-Meier survival analysis shows a significant difference in survival between the patients with myocardial injury and those without myocardial injury (Pϭ0.013 by log-rank test), as shown in Figure 3 . Multivariable analysis of 1-year cumulative survival after TAVI revealed that myocardial injury was an independent predictor for 1-year cumulative mortality (HR, 2.86; 95% CI, 1.28 -6.39; Pϭ0.011), together with preprocedural hospitalization (HR, 2.76; 95% CI, 1.30 -5.83; Pϭ0.008), left ventricular mass index (per g/m 2 ) (HR, 1.01; 95% CI, 1.00 -1.02; Pϭ0.035), and preprocedural mean aortic valve pressure gradient (per mm Hg) (HR, 0.97; 95% CI, 0.94 -1.00; Pϭ0.033).
Discussion
To our knowledge, the present study is the first to describe the clinical value of measuring biochemical markers of myocardial injury after transcatheter aortic valve implantation with the Medtronic-CoreValve device. Serum levels of creatine kinase-MB and cardiac troponin T increase after TAVI, reflecting the procedure-related myocardial injury. Myocardial injury appears to be independently predicted by a longer procedural duration, the absence of ␤-blocker use, the presence of peripheral arterial disease, and a deeper prosthesis insertion. Periprocedural myocardial injury is revealed as an independent predictor of 30-day mortality after TAVI, together with preprocedural hospitalization and left ventricular mass.
After TAVI, both CK-MB and cTnT levels increased in all patients, reaching an average peak level of 3 times the URL. These mean postprocedural cardiac marker levels are comparable with those reported after TAVI (with transfemoral and transapical approach) with the Edwards SAPIEN (Edwards Lifesciences Inc; Irvine, CA) device. 32 The values of postprocedural markers are remarkably low compared with those found after surgical valve replacement and CABG 14, 19, 20, 33, 34 and higher compared with those after PCI. 9, 12, 15, 17, 18 The absence of aortic cross-clamping and cardioplegia in combination with less direct myocardial trauma could explain the relatively lower biomarker levels after TAVI compared with cardiac surgery. 34, 35 More important, no periprocedural myocardial infarction occurred, because none of our patients showed new Q waves or new regional wall motion abnormalities. The higher levels of biomarkers in the patients with TAVI compared with PCI could be explained by the presence of more particle embolization into the coronary circulation, direct myocardial trauma, and especially the presence of concentric left ven- tricular hypertrophy in most of the patients treated with TAVI.
To investigate the etiology of myocardial injury during TAVI, multivariate logistic regression analysis was performed, which showed that a longer procedural duration, the absence of ␤-blocker use, the presence of peripheral arterial disease, and a deeper prosthesis implantation were independent predictors for myocardial injury.
Periprocedural myocardial damage during TAVI is probably, in a large part, attributed to global myocardial ischemia, as a result of a myocardial oxygen demand-supply mismatch. Hypertrophied left ventricles are especially susceptible to subendocardial myocardial damage, because of the reduced myocardial capillary density and high intracavitary pressures, even in the absence of obstructive coronary artery disease. 36, 37 During TAVI, reduced myocardial oxygen supply may result from temporary aortic valve occlusion during balloon valvuloplasty and from hypotension by rapid ventricular pacing, bradycardia due to cardiac conduction disorders, and theoretically distal embolization into the coronary (micro)circulation. Patent coronary arteries were verified with aortic angiography in all patients after prosthesis deployment, which excludes (partial) coronary obstruction as a cause of myocardial injury. Increased myocardial oxygen demand during TAVI may result from a short-term increase in aortic regurgitation (causing increased wall stress due to increased end-diastolic pressures), 38, 39 exposure to intravenous inotropics, and tachycardia. A longer procedural duration is associated with a longer exposure to the previously mentioned factors that result in myocardial oxygen demand-supply mismatch, which explains why procedural duration is a strong predictor for myocardial injury. Alternatively, a longer pro- Values are number (%) or meanϮSD. BMI indicates body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; STS, Society of Thoracic Surgeons; CK-MB, creatine kinase-MB; cTnT, cardiac troponin T; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; EOA, effective orifice area; AVPG, aortic valve pressure gradient; MR, mitral regurgitation; PAP, pulmonary artery pressure; RBCT, red blood cell transfusion; AR, aortic regurgitation; PM, pacemaker; LBBB, left bundle-branch block. cedural duration could be a reflection of the complexity and susceptibility of the treated patient.
A reduction of myocardial oxygen consumption may account for less myocardial injury during TAVI in patients pretreated with a ␤-blocker, as shown in our study. This is in line with studies 40, 41 that have demonstrated the cardioprotective effect of ␤-blockers during PCI.
Our finding of a deeper prosthesis implantation as an independent predictor may be explained by direct injury of the left ventricular outflow tract by the deployed metal frame of the Medtronic-CoreValve device. Accordingly, we previously reported that a deeper insertion of the Medtronic-CoreValve prosthesis was associated with a higher incidence of new left bundle branch block, 42 and injury of the perivalvular myocardium may, in part, be the cause of the injured conduction system. Furthermore, oversizing of the balloonexpandable Edwards prosthesis with respect to the aortic annulus was associated with more myocardial injury in a previous study. 32 Myocardial stretching by both a selfexpandable or a balloon-expandable valve prosthesis probably results in direct myocardial trauma and an increase in cardiac enzyme levels.
Finally, peripheral arterial disease was identified as an independent predictor of myocardial injury. Patients with peripheral arterial disease may have a higher susceptibility to incur myocardial injury, because they have a higher extent of coronary artery disease (as expressed in significantly more prior myocardial infarctions and coronary revascularizations) and because they have a more complex TAVI procedure, leading to a longer procedural duration.
The present study shows that myocardial injury is strongly associated with mortality within 30 days after TAVI. This finding corresponds with many previous reports, showing that peak levels of cardiac troponins and CK-MB are strong predictors for in-hospital mortality and other major adverse events, after PCI, coronary bypass, and heart valve surgery. 11, 13, 14, 33, 43 Myocardial injury was also an independent predictor for 1-year cumulative mortality. This is in line with an earlier report, which found that the degree in increase of cTnT was an independent predictor of cardiac mortality after TAVI. 32 However, as can be seen in the Kaplan-Meier survival curves in Figure 3 , the effect of myocardial injury on 1-year cumulative mortality is rather a reflection of its large impact on 30-day mortality.
Preprocedural hospitalization was a strong predictor for 30-day mortality and cumulative 1-year mortality after TAVI in our study. Most of the patients in our study who were preprocedurally hospitalized for at least 1 week were admitted because of decompensated aortic valve stenosis. These patients consequently had a much poorer functional status than patients who were admitted only 1 day before the procedure. In line with a previous report, we show that patients with TAVI with a poorer preprocedural clinical and functional status have an increased risk of postprocedural mortality. 44 An increased left ventricular mass index was identified in our study as an independent predictor for 30-day mortality and cumulative 1-year mortality after TAVI, an expected finding in line with surgical aortic valve replacement. 36, 45, 46 The underlying mechanisms that can explain the relationship between myocardial injury and 30-day mortality after TAVI remain unclear. The extent of myocardial injury during TAVI is relatively small and diffuse and does not impair myocardial function or cause ventricular arrhythmias leading to sudden cardiac death.
It is, therefore, more likely that the amount of myocardial injury is a reflection of more extensive disease (eg, these patients have more peripheral arterial disease) that makes a patient susceptible for postprocedural cardiovascular morbidity and mortality. Specifically, in these susceptible patients, optimization of the previously mentioned predictive factors may improve their clinical outcome, such as ␤-blocker treatment (if tolerated by the patient with severe aortic stenosis), shortening of procedural duration, and prevention of a deep prosthesis insertion.
This study is limited by the relatively few events, which may have resulted in model overfitting in multivariable analysis. Furthermore, the results were obtained from a prospective observational study, such that the effect of other unmeasured or unknown confounding factors on myocardial injury and mortality cannot be excluded. The amount of myocardial injury was measured with postprocedural cardiac enzyme levels, which did not manifest in new Q waves or new wall motion abnormalities. Cardiac magnetic resonance imaging could be a helpful imaging modality to determine the presence, localization, and amount of myocardial injury after TAVI.
Conclusion
The present study shows that periprocedural myocardial injury occurs in all patients after transcatheter aortic valve implantation, albeit limited, compared with surgical aortic valve replacement. The occurrence of myocardial injury is associated with a longer procedural duration, the absence of ␤-blocker use, peripheral arterial disease, and a deeper prosthesis insertion. Together with preprocedural hospitalization and left ventricular mass, myocardial injury is prognostic for 30-day mortality after TAVI. Certain preventive measures could reduce the amount of myocardial injury and subsequently improve clinical outcome after TAVI. 
